Werewolf Therapeutics Company Leadership
| HOWL Stock | USD 1.40 0.01 0.71% |
About 66 percent of all Werewolf Therapeutics' insiders are acquiring. The analysis of the overall insider sentiment regarding Werewolf Therapeutics suggests that many insiders are confidant. Werewolf Therapeutics employs about 46 people. The company is managed by 9 executives with a total tenure of roughly 108 years, averaging almost 12.0 years of service per executive, having 5.11 employees per reported executive.
Insider Sentiment 66
Mostly Buying
Selling | Buying |
Latest Trades
| 2025-05-14 | Ra Capital Management, L.P. | Acquired 162539 @ 0.98 | View | ||
| 2025-05-12 | Ra Capital Management, L.P. | Acquired 320913 @ 0.86 | View | ||
| 2025-03-27 | Luke Evnin | Disposed 2425 @ 1.05 | View |
Monitoring Werewolf Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. Werewolf Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3266) % which means that it has lost $0.3266 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8281) %, meaning that it created substantial loss on money invested by shareholders. Werewolf Therapeutics' management efficiency ratios could be used to measure how well Werewolf Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.58. The value of Return On Capital Employed is expected to slide to -0.69. At this time, Werewolf Therapeutics' Debt To Assets are quite stable compared to the past year.The value of Common Stock Shares Outstanding is expected to slide to about 35.4 M. Net Loss is expected to rise to about (58.8 M) this year
Werewolf Therapeutics Workforce Comparison
Werewolf Therapeutics is rated # 5 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 389. Werewolf Therapeutics retains roughly 46.0 in number of employees claiming about 12% of equities under Health Care industry.
Werewolf Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Werewolf Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Werewolf Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Werewolf Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Werewolf Therapeutics Notable Stakeholders
A Werewolf Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Werewolf Therapeutics often face trade-offs trying to please all of them. Werewolf Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Werewolf Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Randi MD | Chief Officer | Profile | |
| Timothy CPA | Treasurer CFO | Profile | |
| Cynthia SeidelDugan | Chief Officer | Profile | |
| Ellen MBA | Chief Officer | Profile | |
| Daniel Hicklin | CEO, Founder | Profile | |
| William Winston | Senior Research | Profile | |
| Chulani Karunatilake | Chief Officer | Profile | |
| Steven RPh | Chief Officer | Profile | |
| Reid Leonard | Chief Officer | Profile |
About Werewolf Therapeutics Management Performance
The success or failure of an entity such as Werewolf Therapeutics often depends on how effective the management is. Werewolf Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Werewolf management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Werewolf management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.56) | (0.58) | |
| Return On Capital Employed | (0.66) | (0.69) | |
| Return On Assets | (0.56) | (0.58) | |
| Return On Equity | (0.96) | (0.91) |
Werewolf Therapeutics Workforce Analysis
Traditionally, organizations such as Werewolf Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Werewolf Therapeutics within its industry.Werewolf Therapeutics Manpower Efficiency
Return on Werewolf Therapeutics Manpower
| Revenue Per Employee | 41K | |
| Revenue Per Executive | 209.4K | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 7.8M | |
| Working Capital Per Employee | 2.1M | |
| Working Capital Per Executive | 10.9M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.